Biomarkers in Nutritional Epidemiology: Applications, Needs and New Horizons

Total Page:16

File Type:pdf, Size:1020Kb

Biomarkers in Nutritional Epidemiology: Applications, Needs and New Horizons Hum Genet (2009) 125:507–525 DOI 10.1007/s00439-009-0662-5 REVIEW ARTICLE Biomarkers in nutritional epidemiology: applications, needs and new horizons Mazda Jenab · Nadia Slimani · Magda Bictash · Pietro Ferrari · Sheila A. Bingham Received: 16 January 2009 / Accepted: 27 March 2009 / Published online: 9 April 2009 © Springer-Verlag 2009 Abstract Modern epidemiology suggests a potential many functional dietary biomarkers that, if utilized appro- interactive association between diet, lifestyle, genetics and priately, can be very informative, a better understanding of the risk of many chronic diseases. As such, many epidemio- the interactions between diet and genes as potentially deter- logic studies attempt to consider assessment of dietary mining factors in the validity, application and interpretation intake alongside genetic measures and other variables of of dietary biomarkers is necessary. It is the aim of this interest. However, given the multi-factorial complexities of review to highlight how some important biomarkers are dietary exposures, all dietary intake assessment methods being applied in nutrition epidemiology and to address are associated with measurement errors which aVect dietary some associated questions and limitations. This review also estimates and may obscure disease risk associations. For emphasizes the need to identify new dietary biomarkers and this reason, dietary biomarkers measured in biological highlights the emerging Weld of nutritional metabonomics specimens are being increasingly used as additional or sub- as an analytical method to assess metabolic proWles as mea- stitute estimates of dietary intake and nutrient status. sures of dietary exposures and indicators of dietary pat- Genetic variation may inXuence dietary intake and nutrient terns, dietary changes or eVectiveness of dietary metabolism and may aVect the utility of a dietary biomarker interventions. The review will also touch upon new statisti- to properly reXect dietary exposures. Although there are cal methodologies for the combination of dietary question- naire and biomarker data for disease risk assessment. It is clear that dietary biomarkers require much further research M. Jenab (&) Lifestyle, Environment and Cancer Group, in order to be better applied and interpreted. Future priori- International Agency for Research on Cancer (IARC-WHO), ties should be to integrate high quality dietary intake infor- Lyon, France mation, measurements of dietary biomarkers, metabolic e-mail: [email protected] proWles of speciWc dietary patterns, genetics and novel sta- N. Slimani tistical methodology in order to provide important new Nutritional and Database Resource Team, insights into gene-diet-lifestyle-disease risk associations. International Agency for Research on Cancer (IARC-WHO), Lyon, France M. Bictash Introduction Division of Epidemiology, Public Health and Primary Care, Imperial College London, London, UK Over the past decades, the Weld of nutritional epidemiology has generated a large body of evidence for a potential inter- P. Ferrari Data Collection and Exposure Unit, active association between diet, lifestyle and genetics and European Food Safety Authority (EFSA), Parma, Italy the risk of many chronic diseases. Much of the evidence relating food groups, speciWc S. A. Bingham foods and nutrients to chronic disease risk relies on infor- MRC Centre for Nutritional Epidemiology in Cancer Prevention and Survival, Department of Public Health and Primary Care, mation gathered using various dietary assessment instru- University of Cambridge, Cambridge, UK ments, such as dietary/food frequency questionnaires, food 123 508 Hum Genet (2009) 125:507–525 diaries, food records or 24-h recalls. In most cases, these Applications of dietary biomarkers methodologies require a systematic estimation of the fre- quency of consumption and the portion size of the foods A dietary biomarker can be loosely deWned as a biochemi- consumed as well as more or less detailed information on cal indicator of dietary intake/nutritional status (recent or the recipe ingredients, combinations of foods consumed long term), or it may be an index of nutrient metabolism, or together, and cooking methods, which may aVect the esti- a marker of the biological consequences of dietary intake mation of exposure to a particular dietary component. In (Potischman and Freudenheim 2003). The main advantage addition, the estimation of nutrient intakes relies almost of—or the main assumption behind—dietary biomarkers is entirely on the existence of appropriate and reliable food that they are objective measures and are independent of all composition tables for the target population. When these the biases and errors associated with study subjects and die- issues are coupled to the overwhelming complexities of tary assessment methods (Day et al. 2001; Kaaks et al. diVerent dietary patterns, varying dietary habits, multitudes 2002; Sugar et al. 2007). An ‘ideal’ dietary biomarker of lifestyle confounders, numerous reporting biases, daily would accurately reXect its dietary intake level and it would variations in food intake, combinations of foods, timing of be speciWc, sensitive and applicable to many populations. meals, etc., it is of no surprise that all dietary assessment Existing dietary biomarkers are not ‘ideal’, but they are instruments are associated, to one extent or another, with functional and have found wide spread applicability in diVerent, and sometimes considerable, random and systematic modern nutritional epidemiology. In general, dietary bio- measurement errors. markers can be divided into several classes (recovery, pre- In fact, both nutritional epidemiologists and their many dictive, concentration, replacement) which are described in critics are acutely aware of the complexities and limitations more detail below and in Fig. 1. of various dietary assessment methods (Kaaks and Riboli One of the main applications of dietary biomarkers is to 2005; Michels 2005a, b). This reality of nutritional epidemio- use them as reference measurements to assess the validity logy is being met with intense methodological research and and accuracy of dietary assessment methods (Bingham not only are innovative methods (e.g. internet based assess- 2002; Potischman and Freudenheim 2003; Tasevska et al. ment, use of digital cameras, cellular telephones and personal 2005). The most important dietary biomarkers for this digital assistants) being developed and validated (Dowell and application are the ‘recovery’ biomarkers (i.e. doubly Welch 2006; Kikunaga et al. 2007; Subar et al. 2007; Wang labeled water which is utilized to measure the metabolic et al. 2006), but traditional ones are also constantly being rate and total energy expenditure; urinary total nitrogen/ reWned and improved (e.g. computerized 24-h recall: EPIC potassium which are utilized to estimate total daily protein Soft) (Slimani et al. 1999, 2002; Slimani and Valsta 2002). consumption and potassium intake, respectively) (Bingham More recently, various statistical techniques have also 2003; Day et al. 2001; Livingstone and Black 2003). been developed to account for some of the apparent mea- Recovery biomarkers are based on the concept of the meta- surement errors (Fraser and Yan 2007; GorWne et al. 2007; bolic balance between intake and excretion over a Wxed Rosner et al. 2008) and to better estimate usual food intakes period of time and so provide an estimate of absolute intake (Dodd et al. 2006; Tooze et al. 2006). Nevertheless, in the levels (Kaaks et al. 1997). In other words, excretion levels absence of any ‘independent’ observation of food con- are highly correlated with intake (Bingham 2002). How- sumption, true intake cannot really be assessed. In order to ever, before being applied to the task of questionnaire vali- obtain such ‘independent’ observations (i.e. uncorrelated dation, such biomarkers need to be tested in calibration measurement errors), nutrition epidemiologists have uti- studies under controlled conditions (e.g. in a metabolic lized diVerent biomarkers assessed in biological samples suite) in order to establish that their predictability in not only as measures of dietary intake and nutrient status, humans consuming varying diets is comparable to the die- but also as predictors of disease risk. tary intake method under consideration. Unfortunately, the It is the aim of this review to highlight how some impor- cost and complexity of these techniques makes them tant biomarkers are being applied in the Weld of nutrition largely inapplicable for widespread epidemiologic use and epidemiology and also to address some of the questions and they are best applied either in post hoc analyses of on- shortfalls associated with their use. There is a need to going investigations, or built-in to the design of new develop new dietary biomarkers, and in this respect, the studies, for example the use of doubly labeled water in the review will also highlight metabonomics as an analytical OPEN study (Schatzkin et al. 2003) and markers of method that can be utilized to assess metabolic proWles as potassium and nitrogen in 24 h urine collections (Bingham measures of dietary exposures and indicators of dietary pat- 2002). The recently deWned class of ‘predictive’ biomark- terns or dietary changes. Also, new statistical methodolo- ers can also be utilized to assess the degree of measurement gies for the combination of dietary questionnaire and errors in dietary assessment methods. Like recovery biomarker data will be touched upon. biomarkers,
Recommended publications
  • The Arctic Sea Ice Biomarker IP25: a Review of Current Understanding, Recommendations for Future Research and Applications in Palaeo Sea Ice Reconstructions
    Quaternary Science Reviews 79 (2013) 9e25 Contents lists available at SciVerse ScienceDirect Quaternary Science Reviews journal homepage: www.elsevier.com/locate/quascirev The Arctic sea ice biomarker IP25: a review of current understanding, recommendations for future research and applications in palaeo sea ice reconstructions Simon T. Belt a,*, Juliane Müller b a Biogeochemistry Research Centre, School of Geography, Earth and Environmental Sciences, Plymouth University, Plymouth PL4 8AA, UK b Alfred Wegener Institute for Polar and Marine Research, 27568 Bremerhaven, Germany article info abstract Article history: In recent years, a novel proxy for the past occurrence of Arctic sea ice has been proposed that is based Received 18 June 2012 on the variable marine sedimentary abundance of an organic geochemical lipid derived from sea ice Received in revised form diatoms in the spring. This lipid, termed IP25 (Ice Proxy with 25 carbon atoms), is a highly branched 29 November 2012 isoprenoid mono-unsaturated alkene that appears to be sufficiently stable in sediments to permit Accepted 4 December 2012 meaningful palaeo sea ice reconstructions to be carried out over short- to long-term timescales. Since Available online 17 January 2013 the first proposed use of IP25 as a proxy for palaeo sea ice by Belt et al. (2007), a number of laboratories have measured this biomarker in Arctic sediments and it is anticipated that research activity in this area Keywords: Sea ice will increase further in the future. The content of this review is divided into a number of sections. fi Arctic Firstly, we describe the scienti c basis for the IP25 proxy and its initial discovery in Arctic sea ice, Proxy sedimenting particles and sediments.
    [Show full text]
  • The Biotech/Pharma Perspective
    Biomarkers – The Biotech/Pharma perspective R&D manager - Kim Holmstrøm Bioneer What are Biomarkers? § The modern definition was proposed at the US National Institutes of Health workshop in 1998: “A biomarker is a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes or pharmacological responses to a therapeutic intervention.” 2 What are Biomarkers? Classical Molecular markers • Body temperature § Proteins (e.g. antibodies, • Blood pressure membrane receptors) • Heart rate, etc. § Hormones (e.g. peptide hormones, steroid hormones) • Imaging (MR, PET) § Carbohydrates (e.g. glucose) § Nucleic acids (DNA, mRNA, ncRNA) § Epigenetic factors (methylation, histone modifications) § Lipids (e.g. cholesterol) § Metabolites Biomarkers in human disease and drug development § Diagnostic - Determines the type of disease § Predictive - Identification of subpopulations of patients most likely to respond to a given treatment § Prognostic - Provides information of the likely course of e.g. a cancer disease § Mechanistic - Provides infomation on e.g. specific cell signaling mechanisms that are affected by a drug § Safety - Indicates toxicity effects 4 Genome for science, for health, for individuals Your genome First human genome 1000 Genome 50 Danish families Personal genomes! sequencing Project 150 genomes in total for everyone 1990-2002 2009-2012 The Danish reference (2015-2025) genome The human ! Human genome Healthy lifestyle “building blocks” variation 2011-2015 Prevention of
    [Show full text]
  • Operational Pathways for Biomarker Testing in Nsclc Environmental Scan
    ASSOCIATION OF COMMUNITY CANCER CENTERS OPERATIONAL PATHWAYS FOR BIOMARKER TESTING IN NSCLC ENVIRONMENTAL SCAN TABLE OF CONTENTS Introduction . 1 Current Recommendations for Biomarker Testing in Advanced NSCLC . 1 Barriers to Testing . 2 Opportunities for Overcoming Operational Barriers . 3 Professional Education Pathology Integration Utilizing Lean Methodology Promotion of Cytology in Biomarker Testing Early and Automatic Biomarker Testing Comprehensive Precision Medicine Program Development Summary . 8 Appendix A: Role of Advocacy Groups in Communication, Awareness . 10 LungMATCH LUNGevity Take Aim Appendix B: Additional Studies on Biomarker Testing in NSCLC . 12 References . 13 Acknowledgements . 14 1 | OPERATIONAL PATHWAYS FOR BIOMARKER TESTING IN NSCLC ENVIRONMENTAL SCAN INTRODUCTION A crucial component of care for all patients with advanced stage non-small cell lung cancer (NSCLC) is timely, high-quality comprehensive biomarker testing at diagnosis, progression, and recurrence of disease. Completing comprehensive biomarker testing ensures that patients will be given access to therapies and clinical trials targeted at their cancer’s mutation, and that they will have the information needed to participate in their healthcare decision-making. While actionable biomarkers increasingly guide clinical treatment plans, studies show that several barriers exist to successfully implementing biomarker testing in both the academic and community cancer settings. The Association of Community Cancer Centers (ACCC) has partnered with the Association for Molecular Pathology and LUNGevity in a two-year multiphase effort to aid cancer programs in implementing clinical practice guidelines for biomarker testing for all patients being treated for advanced non-small cell lung cancer. This education project aims to bridge the knowledge gap between the rapidly evolving landscape in actionable biomarkers for patients with advanced NSCLC and integration of biomarker testing into practice through “operational pathways” to implement testing recommendations in every care setting.
    [Show full text]
  • Biomarkers Related to Drug Or Biotechnology Product Development: Context , Structure and Format of Qualification Submissions
    BIOMARKERS RELATED TO DRUG OR BIOTECHNOLOGY PRODUCT DEVELOPMENT: CONTEXT , STRUCTURE AND FORMAT OF QUALIFICATION SUBMISSIONS. E16. http://www.ich.org/LOB/media/MEDIA55 18.pdf International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use Voluntaryyp eXplorator y Data Submissions Training reviewers in the analysis of exploratory biomarker data. Training sponsors in the capabilities of our reviewers for the analysis and interpretation of biomarker data. VOLUNTARY Receiving eXploratoryGenomicGenomic Data DataData Tracking SbSSbSuSubmissionubbmm iss iss ion ion Archiving IPRG (Interdisciplinary Pharmacogenomics Review Group) The image cannot be displayed. Your computer may not have enough memory to open the image, or the image may have been corrupted. Restart y our computer, and then open the file again. If the red x still appears, y ou may hav e to delete the image and then insert it again. Feedback to Sponsor Report VXDSVXDS ReviewReview Public Meetings Education and Workshops Knowledge with Industry Management Exploratory Biomarkers Qualified Biomarkers (VXDS Meetings) (Biomarker Qualification Process) A decision by a sponsor to reanalyze and submit data based on the availability of a newly qualified biomarker should be made in the context of other available nonclinical and clinical data . Regulatory Applications …any additional data required to support qualification for regulatory use will be expected to depend on what data may already be publicly available, data that may lie within
    [Show full text]
  • Programmable Paper-Based Microfluidic Devices for Biomarker Detections
    micromachines Review Programmable Paper-Based Microfluidic Devices for Biomarker Detections Veasna Soum , Sooyong Park, Albertus Ivan Brilian , Oh-Sun Kwon and Kwanwoo Shin * Department of Chemistry, Institute of Biological Interfaces, Sogang University, Seoul 04107, Korea * Correspondence: [email protected] Received: 1 July 2019; Accepted: 1 August 2019; Published: 2 August 2019 Abstract: Recent advanced paper-based microfluidic devices provide an alternative technology for the detection of biomarkers by using affordable and portable devices for point-of-care testing (POCT). Programmable paper-based microfluidic devices enable a wide range of biomarker detection with high sensitivity and automation for single- and multi-step assays because they provide better control for manipulating fluid samples. In this review, we examine the advances in programmable microfluidics, i.e., paper-based continuous-flow microfluidic (p-CMF) devices and paper-based digital microfluidic (p-DMF) devices, for biomarker detection. First, we discuss the methods used to fabricate these two types of paper-based microfluidic devices and the strategies for programming fluid delivery and for droplet manipulation. Next, we discuss the use of these programmable paper-based devices for the single- and multi-step detection of biomarkers. Finally, we present the current limitations of paper-based microfluidics for biomarker detection and the outlook for their development. Keywords: paper-based microfluidic device; flow control; droplet actuation; multi-step assay; biomarker detection; digital microfluidic device 1. Introduction Because of cost, disposable, paper-based microfluidic devices have become an attractive tool for point-of-care testing (POCT) and medical screening in the developing world. Paper-based, continuous-flow microfluidic (p-CMF) devices were first invented in 1949 by Müller and Clegg [1]; however, no proof of concept for the use of such devices for portable, onsite detection in biosensing applications was reported until 2007 when Whitesides’ group published their report [2].
    [Show full text]
  • Policy Issues for the Development and Use of Biomarkers in Health
    Policy Issues for the Development and Use of Biomarkers in Health Organisation for Economic Co-operation and Development (OECD) The OECD is a unique forum where governments work together to address the economic, social and environmental challenges of globalisation. The OECD is also at the forefront of efforts to understand and to help governments respond to new developments and concerns, such as corporate governance, the information economy and the challenges of an ageing population. The Organisation provides a setting where governments can compare policy experiences, seek answers to common problems, identify good practice and work to co-ordinate domestic and international policies. The OECD member countries are: Australia, Austria, Belgium, Canada, Chile, the Czech Republic, Denmark, Estonia, Finland, France, Germany, Greece, Hungary, Iceland, Ireland, Israel, Italy, Japan, Korea, Luxembourg, Mexico, the Netherlands, New Zealand, Norway, Poland, Portugal, the Slovak Republic, Slovenia, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The European Union takes part in the work of the OECD. OECD Directorate for Science, Technology and Industry (DSTI) The Directorate for Science, Technology and Industry leads the OECD’s work on knowledge-based sources of economic and social growth and, more specifically, on the translation of science, technology and knowledge into innovation. For further information about our work on biotechnology please visit www.oecd.org/sti/biotechnology © OECD 2011 Cover photo: © rolffimages - Fotolia.com 2 POLICY ISSUES FOR THE DEVELOPMENT AND USE OF BIOMARKERS IN HEALTH – © OECD 2011 Foreword Application of biomarkers in the field of human health is improving our understanding of disease, and will provide new knowledge of disease mechanisms and processes providing a means for improved health management through the earlier diagnosis of disease and the delivery of more efficacious and safer therapies.
    [Show full text]
  • Clinical Development Success Rates 2006-2015
    Clinical Development Success Rates 2006-2015 Biomedtracker Pharma intelligence | June 2016 About BIO BIO is the world’s largest trade association representing biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and in more than 30 other nations. BIO members are involved in the research and development of innovative healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the BIO International Convention, the world’s largest gathering of the biotechnology industry, along with industry- leading investor and partnering meetings held around the world. About Biomedtracker BioMedTracker, a subscription-based product of Informa, tracks the clinical development and regulatory history of investigational drugs to assess its Likelihood of Approval (LOA) by the FDA. BioMedTracker is populated in near real-time with updated information from press releases, corporate earnings calls, investor and medical meetings and numerous other sources. About Amplion Amplion is the leading biomarker business intelligence company, and its flagship product BiomarkerBase™, along with consulting services and free reports, deliver insights that inform key strategic decisions for drug and diagnostic test developers. Since 2012 Amplion has helped large and small companies alike make the best use of biomarkers in advancing precision therapeutics and next generation diagnostics. BiomarkerBase is a subscription-based service that tracks biomarker usage in clinical trials, drug labels, and tests (including laboratory-developed, FDA-cleared, and FDA- approved tests). BiomarkerBase is updated weekly with information from these sources and publications, using supervised machine learning algorithms for natural language processing (Amplion BiomarkerEngine) to identify biomarkers. 2 | BIO Industry Analysis Executive Summary This is the largest study of clinical drug development success rates to date.
    [Show full text]
  • Exoplanet Biosignatures: a Review of Remotely Detectable Signs of Life
    ASTROBIOLOGY Volume 18, Number 6, 2018 Mary Ann Liebert, Inc. DOI: 10.1089/ast.2017.1729 Exoplanet Biosignatures: A Review of Remotely Detectable Signs of Life Edward W. Schwieterman,1–5 Nancy Y. Kiang,3,6 Mary N. Parenteau,3,7 Chester E. Harman,3,6,8 Shiladitya DasSarma,9,10 Theresa M. Fisher,11 Giada N. Arney,3,12 Hilairy E. Hartnett,11,13 Christopher T. Reinhard,4,14 Stephanie L. Olson,1,4 Victoria S. Meadows,3,15 Charles S. Cockell,16,17 Sara I. Walker,5,11,18,19 John Lee Grenfell,20 Siddharth Hegde,21,22 Sarah Rugheimer,23 Renyu Hu,24,25 and Timothy W. Lyons1,4 Abstract In the coming years and decades, advanced space- and ground-based observatories will allow an unprecedented opportunity to probe the atmospheres and surfaces of potentially habitable exoplanets for signatures of life. Life on Earth, through its gaseous products and reflectance and scattering properties, has left its fingerprint on the spectrum of our planet. Aided by the universality of the laws of physics and chemistry, we turn to Earth’s biosphere, both in the present and through geologic time, for analog signatures that will aid in the search for life elsewhere. Considering the insights gained from modern and ancient Earth, and the broader array of hypothetical exoplanet possibilities, we have compiled a comprehensive overview of our current understanding of potential exoplanet biosignatures, including gaseous, surface, and temporal biosignatures. We additionally survey biogenic spectral features that are well known in the specialist literature but have not yet been robustly vetted in the context of exoplanet biosignatures.
    [Show full text]
  • BMS Translational Medicine
    Bristol-Myers Squibb is actively conducting translational medicine research to further our understanding of cancer biology and to identify which patient populations may be more likely to derive benefit from Immuno-Oncology (I-O) agents. Biomarkers and Clinical Exploratory Imaging and Bioinformatics and Pharmacodiagnostics Pharmacology and Translational Technologies Integrated Sciences (PDx) Pharmacometrics Research / Collaboration Biomarkers and Clinical Exploratory Imaging and Bioinformatics and Pharmacodiagnostics Pharmacology and Translational Technologies Integrated Sciences (PDx) Pharmacometrics Research / Biomarkers and Pharmacodiagnostics (PDx) Our vision is for tumor biology to inform treatment selection for each patient at each stage of therapy Collaboration Areas of Focus in Biomarker Research Inflamed Tumor Tumor Antigens: Microenvironment: Biomarkers to identify Biomarkers within the tumor, T hypermutation and neo- cells or microenvironment that antigens that may predict may predict response response to I-O Inflamed Tumor Tumor Antigen Tumor Immune Host Environment: Suppression: Biomarkers to characterize the Biomarkers related to host environment, beyond the mechanisms of resistance via Tumor Immune tumor microenvironment, which specific immune pathways that Suppression may reveal immune-related may be addressed with I-O mechanisms predictive of treatment response Pharmacodiagnostics (PDx): Diagnostic tests for biomarker expression that may predict patient response prior to treatment Areas of Focus in Biomarker Research Inflamed
    [Show full text]
  • Biomarkers: Potential Uses and Limitations
    NeuroRx௡: The Journal of the American Society for Experimental NeuroTherapeutics Biomarkers: Potential Uses and Limitations Richard Mayeux Gertrude H. Sergievsky Center and the Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, College of Physicians and Surgeons, Columbia University, New York, New York 10032 Summary: Biomarkers provide a dynamic and powerful ap- from the earliest manifestations to the terminal stages. This proach to understanding the spectrum of neurological disease brief review describes the major uses of biomarkers in clinical with applications in observational and analytic epidemiology, investigation. Careful assessment of the validity of biomarkers is randomized clinical trials, screening and diagnosis and prog- required with respect to the stage of disease. Causes of variability nosis. Defined as alterations in the constituents of tissues or in the measurement of biomarkers range from the individual to the body fluids, these markers offer the means for homogeneous laboratory. Issues that affect the analysis of biomarkers are classification of a disease and risk factors, and the can extend discussed along with recommendations on how to deal with our base information about the underlying pathogenesis of dis- bias and confounding. Key Words: Antecedent biomarkers, ease. Biomarkers can also reflect the entire spectrum of disease diagnostic biomarkers, variability, reliability, validity. INTRODUCTION fections, immunological and genetic disorders, and can- cer are well known.1,3 Their use in research has
    [Show full text]
  • Importance of Preoperative Knowledge of the Biomarker HE4 In
    ANTICANCER RESEARCH 37 : 2697-2702 (2017) doi:10.21873/anticanres.11619 Importance of Preoperative Knowledge of the Biomarker HE4 in Early-stage Endometrial Cancer Regarding Surgical Management JIRI PRESL 1, PETRA OVESNA 2, ZDENEK NOVOTNY 1, PAVEL VLASAK 1, JIRI BOUDA 1, JAN KOSTUN 1, ONDREJ TOPOLCAN 3, RADEK KUCERA 3, MARKETA BEDNARIKOVA 4 and VIT WEINBERGER 5 1Department of Gynecology and Obstetrics, University Hospital Pilsen, Pilsen, Czech Republic; 2Institute of Biostatistics and Analyses, Faculty of Medicine, Masaryk University, Brno, Czech Republic; 3Laboratory of Immunoanalysis, Department of Nuclear medicine, University Hospital in Pilsen, Pilsen, Czech Republic; 4Clinic of Internal Medicine – Hematology and Oncology, University Hospital in Brno and Masaryk University, Brno, Czech Republic; 5Department of Gynecology and Obstetrics, University Hospital in Brno and Masaryk University, Brno, Czech Republic Abstract. Aim: To analyze the utility of HE4 assessment in Endometrial cancer (EC) patients often exhibit signs and preoperative management of patients with early-stage symptoms, such as postmenopausal bleeding that lead to endometrial cancer for stratification into low-risk and high- diagnosis of the malignancy in early stages of the disease. As risk groups. Patients and Methods: The following data were a result, more than 70% of EC cases are diagnosed at an early prospectively collected from patients operated for endometrial stage with a favorable prognosis (1). Abdominal ultrasound cancer from 05/2012 till 9/2016; age, HE4, CA125, expert (US) combined with transvaginal ultrasound of the pelvis ultrasound examination of the pelvis, histotype, grade, FIGO (TVUS) belong to obligatory imaging methods for EC staging stage. Results: In total, 124 patients were enrolled.
    [Show full text]
  • Demosponge Steroid Biomarker 26-Methylstigmastane Provides Evidence for Neoproterozoic Animals
    ARTICLES https://doi.org/10.1038/s41559-018-0676-2 Demosponge steroid biomarker 26-methylstigmastane provides evidence for Neoproterozoic animals J. Alex Zumberge1, Gordon D. Love 1*, Paco Cárdenas 2, Erik A. Sperling3, Sunithi Gunasekera2, Megan Rohrssen4, Emmanuelle Grosjean5, John P. Grotzinger6 and Roger E. Summons7 Sterane biomarkers preserved in ancient sedimentary rocks hold promise for tracking the diversification and ecological expan- sion of eukaryotes. The earliest proposed animal biomarkers from demosponges (Demospongiae) are recorded in a sequence around 100 Myr long of Neoproterozoic–Cambrian marine sedimentary strata from the Huqf Supergroup, South Oman Salt Basin. This C30 sterane biomarker, informally known as 24-isopropylcholestane (24-ipc), possesses the same carbon skeleton as sterols found in some modern-day demosponges. However, this evidence is controversial because 24-ipc is not exclusive to demosponges since 24-ipc sterols are found in trace amounts in some pelagophyte algae. Here, we report a new fossil sterane biomarker that co-occurs with 24-ipc in a suite of late Neoproterozoic–Cambrian sedimentary rocks and oils, which possesses a rare hydrocarbon skeleton that is uniquely found within extant demosponge taxa. This sterane is informally designated as 26-methylstigmastane (26-mes), reflecting the very unusual methylation at the terminus of the steroid side chain. It is the first animal-specific sterane marker detected in the geological record that can be unambiguously linked to precursor sterols only reported from extant demosponges. These new findings strongly suggest that demosponges, and hence multicellular animals, were prominent in some late Neoproterozoic marine environments at least extending back to the Cryogenian period.
    [Show full text]